Ileal Pouch Studies
Research & Support

Review of data supporting VSL#3® for the care of patients with an ileal pouch.

Conditions such as ulcerative colitis, if severe enough, may require that patients have surgery to remove the colon. Following surgery, an ileal pouch, or internal reservoir is often created using the patient's remaining bowel.

Pouchitis is an inflammation of the lining of the pouch and is believed to be related to an overgrowth of bacteria. Pouchitis can affect up to 50% of patients with an ileal pouch and is often recurrent. A common symptom of pouchitis is an increase in the number of daily bowel movements, also known as stool frequency.

Ileal Pouch Studies

VSL#3® for the care of patients with an ileal pouch

The median stool frequency of pouch patients consuming VSL#3® on a daily basis progressively decreased ( P<0.01 at 3 months; P<0.001 at 6, 9, and 12 months).

Further, the median Inflammatory Bowel Disease Questionnaire (IBDQ) score improved significantly in patients consuming VSL#3® compared to those receiving placebo ( P<0.001).

Only 15% of chronic pouchitis patients treated with VSL#3® had relapses compared with 100% of similar patients treated with placebo over a 9 month study period (P<0.001).

VSL#3® is the only probiotic recognized as an effective tool for the management of pouchitis by the American College of Gastroenterology, the British Society of Gastroenterology and the German Association of Gastroenterology. Three double-blind, placebo-controlled trials have been published which shows that VSL#3® aids in the management of pouchitis.

Original Articles of VSL#3® for the care of
patients with an Ileal Pouch

Mimura T et al: Gut 2004; 53:108-114.
Gionchetti P et al: Gastroenterology 2003; 124:1202-09.
Gionchetti P et al: Gastroenterology 2000; 119:305-309.

Ileal Pouch Studies